Brokerages Set LifeStance Health Group, Inc. (NASDAQ:LFST) Price Target at $12.62

LifeStance Health Group, Inc. (NASDAQ:LFST) has received a consensus rating of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $12.8750.

A number of equities research analysts have recently issued reports on the stock. KeyCorp increased their price target on shares of LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. BTIG Research boosted their price objective on shares of LifeStance Health Group from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. JPMorgan Chase & Co. upped their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday, August 14th. The Goldman Sachs Group initiated coverage on shares of LifeStance Health Group in a research note on Friday, June 5th. They issued a “neutral” rating and a $9.00 target price on the stock. Finally, Canaccord Genuity Group raised their price target on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday.

LifeStance Health Group Stock Performance

NASDAQ:LFST opened at $12.97 on Thursday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. LifeStance Health Group has a 52-week low of $4.77 and a 52-week high of $13.28. The firm has a market cap of $4.96 billion, a price-to-earnings ratio of 99.78 and a beta of 1.22. The business’s fifty day moving average is $11.67 and its 200 day moving average is $9.00.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. The business had revenue of $435.35 million during the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The firm’s revenue was up 26.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.01) EPS. Research analysts predict that LifeStance Health Group will post 0.16 EPS for the current year.

Insider Activity

In related news, COO Lisa K. Miller sold 47,912 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the completion of the transaction, the chief operating officer directly owned 281,289 shares in the company, valued at $3,051,985.65. The trade was a 14.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.62, for a total value of $144,890,858.34. Following the transaction, the insider owned 98,101,407 shares of the company’s stock, valued at approximately $1,041,836,942.34. The trade was a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 14,671,917 shares of company stock worth $155,493,415. Company insiders own 3.50% of the company’s stock.

Institutional Trading of LifeStance Health Group

A number of large investors have recently modified their holdings of the business. Larson Financial Group LLC increased its position in shares of LifeStance Health Group by 19,952.6% in the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after purchasing an additional 3,791 shares during the last quarter. KBC Group NV purchased a new stake in LifeStance Health Group in the first quarter valued at approximately $29,000. IFP Advisors Inc lifted its position in LifeStance Health Group by 316.5% during the second quarter. IFP Advisors Inc now owns 3,694 shares of the company’s stock valued at $40,000 after purchasing an additional 2,807 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in LifeStance Health Group by 359.1% during the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after purchasing an additional 5,404 shares during the last quarter. Finally, Bayesian Capital Management LP bought a new stake in LifeStance Health Group during the second quarter valued at approximately $52,000. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group News Summary

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Barclays raised its price target for LifeStance Health Group from $13 to $15 and maintained an “overweight” rating, implying further upside from the stock’s recent level. Barclays price target report
• Positive Sentiment: Zacks highlighted LFST as a strong momentum candidate, reinforcing investor interest after the shares’ substantial appreciation over the past year. Zacks momentum stock analysis
• Positive Sentiment: The company’s latest quarterly results showed strong operating momentum: revenue increased 26.1% year over year to $435.4 million, while adjusted earnings of $0.06 per share exceeded expectations of $0.03. The company is also projected to remain profitable for the full year.
• Neutral Sentiment: LifeStance announced a secondary offering alongside a share repurchase program. The repurchase could help absorb some of the shares being offered and support the stock, although the overall effect depends on the offering size and terms. LifeStance secondary offering and share repurchase announcement
• Neutral Sentiment: Brokerages collectively rate LFST a “Moderate Buy,” suggesting generally favorable expectations but not unanimous conviction.
• Negative Sentiment: The secondary offering may create additional share supply and weigh on the stock in the near term, particularly after its sharp run-up. The stock also trades at a high valuation—roughly 100 times earnings—leaving it sensitive to changes in growth expectations.

About LifeStance Health Group

LifeStance Health Group, Inc is a behavioral health care company that provides outpatient mental health services through in-person and virtual appointments. Its platform connects patients with psychiatrists, psychologists, psychiatric nurse practitioners, therapists and other licensed clinicians.

The company offers services that may include psychotherapy, psychiatric evaluations, medication management and treatment for conditions such as anxiety, depression, attention-deficit/hyperactivity disorder and other behavioral health needs.